UroGen Pharma Ltd. Class Action Overview
The Gross Law Firm is alerting investors of UroGen Pharma Ltd. regarding the pending class action lawsuit related to the company's recent performance and regulatory challenges.
Details of the Class Action
Shareholders who acquired shares of UroGen Pharma Ltd. (NASDAQ: URGN) during the class period are urged to reach out to The Gross Law Firm. This period is crucial as it includes all transactions from July 27, 2023, to May 15, 2025. Those interested in a potential lead plaintiff position can express their interest, but it is not necessary to claim any recovery.
Allegations Against UroGen Pharma Ltd.
The complaint alleges that during the class period, significant misstatements and omissions occurred from company executives. These included failing to inform investors about the ENVISION clinical study's limitations in demonstrating the effectiveness of UGN-102 due to its deficient design. Additionally, concerns were raised regarding the company's disregard for the FDA's warnings about their study, which could jeopardize NDA approval for UGN-102. Misleading statements about UroGen's business operations have been called into question, potentially inflating stock prices artificially.
Important Deadlines for Shareholders
The deadline for shareholders to register for participation in this class action lawsuit is July 28, 2025. It's important for investors to act promptly to secure their rights and maintain compliance with this timeline. By registering, shareholders will also gain access to a monitoring service that provides updates on the case's status.
Next Steps for Investors
Investors should not hesitate to register for this class action if they purchased shares during the specified timeframe. The Gross Law Firm is committed to helping affected investors navigate this situation without any cost or obligation to them. Their primary goal is to restore shareholder rights and pursue accountability for any misconduct leading to financial harm.
About The Gross Law Firm
The Gross Law Firm is a well-respected class action firm dedicated to advocating for investors' rights and ensuring that corporations practice transparency and fairness. Their mission encompasses holding companies accountable for any fraudulent practices that mislead shareholders. Attorney advertising is essential, and past outcomes do not guarantee future results.
Contact Information
If you need further assistance, The Gross Law Firm can be reached at their New York City office.
ADDRESS: 15 West 38th Street, 12th floor, New York, NY 10018
PHONE: (646) 453-8903
Frequently Asked Questions
What should I do if I purchased shares of UroGen Pharma Ltd.?
Contact The Gross Law Firm to inquire about your eligibility to participate in the class action lawsuit.
What is the deadline for registering as a lead plaintiff?
The deadline to seek lead plaintiff status is July 28, 2025.
What allegations are being made against UroGen Pharma Ltd.?
Allegations include misleading statements regarding the effectiveness of UGN-102 and ignoring FDA warnings about study design.
Is there a cost to participate in the class action?
No, there is no cost or obligation for shareholders to register and participate.
How can I get updates on the class action status?
Upon registering, you will receive updates through a monitoring service provided by The Gross Law Firm.
